EGFR and non-small cell lung carcinoma: Among NSCLC patients with abnormal EGFR, the overall survival curves of patients treated with EGFR-TKI did not differ significantly from those treated with first-line chemotherapy, and even their tendency to have higher survival rates in the short term disappeared (Figure 2H).